So, sometime in the next 3 weeks, Todos will do about a 1:25 R/S and uplist to the Nasdaq, raising about $6m off 25million pre-r/s shares. This will then be a low float biotech on the nasdaq with 5 million post R/S shares, 2 million of which Amarantus will own for a temporarily illiquid asset on the books of about $12m.

After that, we can hope for release of full Lympro pet data set, while further lympro and cancer diagnostic research is completed, and hopefully some revenue is recognized over the next year such that additional dilution can be pushed off as far as possible and is completed on favorable terms. Given a runway of 18-24 months, we should expect secondary raises after good news far before they run out of cash. Would not be surprised to see a secondary this time next year. So hopefully the share price can be resilient. Amarantus shares should unlock prior to this secondary.